SHPG - Shire plc

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
151.27
+4.07 (+2.76%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close147.20
Open146.02
Bid0.00 x 0
Ask0.00 x 0
Day's Range145.87 - 151.49
52 Week Range137.17 - 192.15
Volume1,408,601
Avg. Volume1,012,604
Market Cap43.804B
Beta1.88
PE Ratio (TTM)28.58
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.92 (0.63%)
Ex-Dividend Date2017-09-07
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 days ago

    Roche, Shire court fight escalates over haemophilia drug

    Roche's patent dispute with London-listed Shire over the Swiss drugmaker's new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine. Shire's motion for a preliminary injunction is part of an ongoing case in which it contends Roche infringed on a key patent to develop Hemlibra, approved in November by the U.S. Food and Drug Administration.

  • Shire's New Formulation of Oncaspar Gets Approval in Europe
    Zacks4 days ago

    Shire's New Formulation of Oncaspar Gets Approval in Europe

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.

  • Barrons.com6 days ago

    This Porridge Is Too Hot: Valeant Bears Abandon the Stock

    Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.

  • Reuters13 days ago

    Shire in deal to develop a new way to administer hemophilia drug

    Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A. The company, Rani Therapeutics, has developed a technology that will help oral delivery of peptides, proteins and therapeutic antibodies which to date could be delivered only through injections. Once delivered through Rani Pill - the oral delivery technology - the drug stays in the body until it enters the small intestine and transfers the medicine into the intestinal wall, the companies said.

  • How Financially Strong Is Shire plc (LSE:SHP)?
    Simply Wall St.13 days ago

    How Financially Strong Is Shire plc (LSE:SHP)?

    With a market capitalization of £32.95B, Shire plc (LSE:SHP) falls in the category of stocks popularly identified as large-caps. These are established companies that attract investors due to diversified revenueRead More...

  • Barrons.com28 days ago

    Is Shire Bleeding Out?

    Today, Shire (SHPG) appointed a new chief financial officer. The shares are sliding lower today after its rival Roche (RHHBY) unveiled study results that showed its Hemlibra hemophilia drug trial reduced treated bleeds in hemophilia A patients without indicators. The news is an added blow for Shire.

  • Why Shire plc (LSE:SHP) Could Be A Buy
    Simply Wall St.28 days ago

    Why Shire plc (LSE:SHP) Could Be A Buy

    Let’s talk about the popular Shire plc (LSE:SHP). The company’s shares saw significant share price volatility over the past couple of months on the LSE, rising to the highs ofRead More...

  • Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval
    Zackslast month

    Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

    Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

  • Shire Gets Positive CHMP Opinion for Hemophilia A Drug
    Zackslast month

    Shire Gets Positive CHMP Opinion for Hemophilia A Drug

    Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

  • The Only 3 Big Pharma Companies Growing Market Share
    Motley Foollast month

    The Only 3 Big Pharma Companies Growing Market Share

    Most big pharma companies will actually lose market share over the next few years. These three will gain market share -- but in very different ways.

  • Capital Cubelast month

    ETFs with exposure to Shire Plc : November 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
    Zacks2 months ago

    Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

    Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

  • MarketWatch2 months ago

    Fund manager, analysts make the case for this ‘loathed’ pharma stock

    Irish pharmaceutical giant Shire has seen its shares slump this year, turning in one of the worst performances among United Kingdom-listed blue chips. The bear case may have some cracks in it, however....

  • American City Business Journals2 months ago

    Shire to sell 100-employee Milford site as part of manufacturing slim-down

    Rare disease drugmaker Shire, one of the state’s biggest life science employers, is in active negotiations to sell one of its manufacturing sites in Milford, according to a top executive. Shire (SHPG) announced as part of its third quarter earnings on Friday that it plans to implement a cost-cutting program targeting its manufacturing operations. In an interview, the company’s head of technical operations, Matt Walker, told the Business Journal that Shire is divesting five of its 17 manufacturing sites worldwide, including the 99,000 square-foot plant in Milford.

  • Reuters2 months ago

    Shire to make genetic disease drug itself to secure supply

    Shire (SHP.L) will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit. "We delivered strong growth this quarter with product sales up 7 percent to $3.5 billion(£2.67 billion) despite a Cinryze supply shortage and a Lialda generic entry," Shire Chief Executive Flemming Ornskov said in a statement. Ornskov said Shire's immunology drugs to treat diseases like Guillain-Barre syndrome performed strongly in the quarter and growth in the franchise it acquired by buying Baxalta last year rose from a historical rate of 6-8 to 21 percent year to date.

  • Reuters2 months ago

    Shire to make genetic disease drug itself to secure supply

    Shire will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit. "We delivered strong growth this quarter with product sales up 7 percent to $3.5 billion despite a Cinryze supply shortage and a Lialda generic entry," Shire Chief Executive Flemming Ornskov said in a statement. Ornskov said Shire's immunology drugs to treat diseases like Guillain-Barre syndrome performed strongly in the quarter and growth in the franchise it acquired by buying Baxalta last year rose from a historical rate of 6-8 to 21 percent year to date.

  • Associated Press2 months ago

    Shire beats 3Q profit forecasts

    On a per-share basis, the Dublin-based company said it had net income of $1.81. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to $3.81 per share. The results ...

  • Capital Cube2 months ago

    ETFs with exposure to Shire Plc : October 23, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Shire's New Formulation of Oncaspar Gets CHMP Recommendation
    Zacks2 months ago

    Shire's New Formulation of Oncaspar Gets CHMP Recommendation

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

  • Capital Cube2 months ago

    ETFs with exposure to Shire Plc : October 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Shire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017
    Capital Cube2 months ago

    Shire Plc :SHPG-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017

    Categories: Yahoo FinanceGet free summary analysis Shire Plc reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 3,822.03 million, Net Earnings of USD 246.41 million. Gross margins narrowed from 58.29% to 57.33% compared to the same period last year, operating (EBITDA) margins now 35.09% from 30.14%. Change in operating cash ... Read more (Read more...)

  • The Wall Street Journal2 months ago

    Shire Alleges Allergan Blocked Drug From Medicare Contracts

    Shire filed an antitrust suit against Allergan, alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug.

  • Reuters3 months ago

    Shire sues Allergan in U.S. over dry eye drug

    In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.

  • Reuters3 months ago

    Shire sues Allergan in U.S. over dry eye drug

    Allergan Plc was sued on Monday by Shire Plc for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease. In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra.